Rawojć Kamila, Ahmed Mansoor M, Mukhtiar Ayesha, Łukowiak Magdalena, Kisielewicz Kamil
National Institute of Oncology, Maria Sklodowska-Curie Memorial Institute, 31-115 Cracow, Poland.
Albert Einstein College of Medicine, Montefiore Einstein, New York, NY 10461, USA.
Pharmaceutics. 2025 Apr 11;17(4):508. doi: 10.3390/pharmaceutics17040508.
Glioblastoma multiforme remains one of the most aggressive and treatment-resistant brain tumors that necessitate innovative therapeutic approaches. Nanomedicine has emerged as a promising strategy to enhance radiation therapy by improving drug delivery, radiosensitization, and real-time treatment monitoring. Stimuli-responsive nanoparticles can overcome limitations of the blood-brain barrier, modulate tumor microenvironment, and facilitate targeted therapeutic interventions. The integration of nanotechnology with proton and X-ray radiotherapy offers improved dose precision, enhanced radiosensitization, and adaptive treatment strategies. Furthermore, Artificial Intelligence-driven nanoparticle designs are optimizing therapeutic outcomes by tailoring formulations to tumor-specific characteristics. While promising, clinical translation remains a challenge that requires rigorous validation to ensure safety and efficacy. This review highlights advancements in nanomedicine-enhanced radiotherapy and future directions for glioblastoma multiforme treatment.
Expert Opin Drug Deliv. 2024-12
Expert Opin Drug Deliv. 2020-11
Neuroscience. 2024-11-12
Front Pharmacol. 2025-1-6
Expert Opin Drug Deliv. 2016-11
Nanomaterials (Basel). 2023-10-30
J Nanobiotechnology. 2023-7-20
Technol Cancer Res Treat. 2023
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023
Adv Mater. 2024-5
Nat Commun. 2022-12-27
ACS Nano. 2022-7-26
ACS Nano. 2022-5-24